Anti-CD20 should be the first line treatment in high risk membranous nephropathy

Abstract Membranous nephropathy (MN) is a common cause of nephrotic syndrome (NS) in adults and if untreated can progress to endstage kidney disease. Factors considered to place a patient at high or very high risk for progression include elevated serum creatinine at baseline, declining kidney function, persistent heavy proteinuria (> 8 g/24hours) or persistent NS or presence of life-threatening complications related to NS (such as venous thromboembolic events) or very high anti-PLA2R antibody titers (> 150 u/ml). Patients who are at high or very high risk of progression should be treated with immunosuppression therapy in order to induce remission of proteinuria and to avoid progressive loss of kidney function. Traditional forms of immunosuppression for patients with MN have included the use of cyclic courses of corticosteroids with cyclophosphamide or calcineurin inhibitors. These forms of therapy are associated with significant toxicity, e.g. corticosteroids (infections, diabetes, weight gain), cyclophosphamide (infertility, severe leukopenia, malignancy), calcineurin inhibitors (hypertension, nephrotoxicity). The introduction of anti-CD20 + B cell therapies in the late 1990 s has changed the landscape. In this article we will argue that anti-CD20 + B therapy should be the treatment of choice for patients at high/very high risk of progression when considering its efficacy and side-effect profile.